drugset / Trial / NCT02020486

A Multiple Dose Pharmacokinetic Study of Perampanel in Korean Healthy Subjects

NCT02020486

Phase 1 Completed 20 enrolled Eisai Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will consist of 2 phases: Pretreatment Phase and Treatment Phase. The Pretreatment Phase will have 2 time points: Screening and Baseline. Subjects will be admitted to the clinical study ward the day before starting the study drug administration (Day -1) for PK and safety assessments during Treatment Phase, and discharged at Day 33 (group A) and Day 47 (group B). Post-test will be done at Day 37 (+/-1), Day 42 (+3) (group A) and Day 51 (+/-1), Day 56 (+3) (group B). Study medication will be administered with 240 mL of room temperature water

Timeline

Start
2013-12
Primary completion
2014-03
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Perampanel Small molecule 4 mg Oral
Subject Perampanel Small molecule 6 mg Oral

Indications

No indication recorded.